Knockout-mouse experiments indicate that the CCL20–CCR6 axis has a dominant role in IL-17-driven psoriasiform inflammation but a more limited role in papain-induced type 2 inflammation.
Key findings
- In the psoriasis model, loss of CCL20 or CCR6 markedly reduced severity scores, Th17 cytokines and γδlow+ T-cell migration. In the papain model, severity fell by about 40%, with lower IL-4, IgE and mast-cell measures, while broader immune effects were limited.
Why this matters globally
The work helps prioritize immune targets, suggesting that CCL20–CCR6 may be more relevant to IL-17-driven disease than as a broad target for type 2 inflammation.
Thai researcher contribution
Researchers from Chulalongkorn University contributed to experimental work linking basic immune biology with inflammatory skin-disease questions.
Limitations to consider
This is preclinical mouse evidence. The models do not capture the full complexity of human disease, and there are no patient data on safety, dosing or efficacy of pathway inhibition.